Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phantoms, Imaging | 3 | 2017 | 189 | 0.930 |
Why?
|
| Film Dosimetry | 2 | 2017 | 11 | 0.720 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2017 | 36 | 0.710 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 177 | 0.540 |
Why?
|
| Water | 2 | 2015 | 228 | 0.470 |
Why?
|
| Algorithms | 1 | 2017 | 1194 | 0.390 |
Why?
|
| Radiometry | 1 | 2011 | 64 | 0.380 |
Why?
|
| Radiosurgery | 1 | 2011 | 66 | 0.370 |
Why?
|
| Neoplasms | 2 | 2017 | 1660 | 0.320 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2017 | 30 | 0.280 |
Why?
|
| Radiotherapy Dosage | 3 | 2017 | 125 | 0.270 |
Why?
|
| Graft vs Host Disease | 2 | 2015 | 163 | 0.220 |
Why?
|
| Gamma Rays | 2 | 2015 | 64 | 0.170 |
Why?
|
| Fracture Healing | 1 | 2018 | 29 | 0.170 |
Why?
|
| Femoral Fractures | 1 | 2018 | 45 | 0.160 |
Why?
|
| Femur | 1 | 2018 | 113 | 0.160 |
Why?
|
| Radiation | 1 | 2016 | 7 | 0.150 |
Why?
|
| Osteogenesis | 1 | 2018 | 152 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 2 | 2015 | 561 | 0.150 |
Why?
|
| Medulloblastoma | 1 | 2016 | 24 | 0.150 |
Why?
|
| HLA Antigens | 1 | 2016 | 82 | 0.140 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 30 | 0.140 |
Why?
|
| Radiation Dosage | 1 | 2018 | 419 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 756 | 0.130 |
Why?
|
| Nitric Oxide Donors | 1 | 2015 | 54 | 0.130 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 86 | 0.130 |
Why?
|
| Necrosis | 1 | 2015 | 239 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2015 | 97 | 0.130 |
Why?
|
| T-Box Domain Proteins | 1 | 2014 | 29 | 0.130 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 1849 | 0.130 |
Why?
|
| Cisplatin | 1 | 2015 | 192 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2015 | 190 | 0.120 |
Why?
|
| Th1 Cells | 1 | 2014 | 101 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2015 | 178 | 0.120 |
Why?
|
| S-Nitrosoglutathione | 1 | 2015 | 87 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 510 | 0.120 |
Why?
|
| Th17 Cells | 1 | 2014 | 116 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2014 | 241 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 245 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2015 | 219 | 0.110 |
Why?
|
| Particle Accelerators | 1 | 2012 | 10 | 0.110 |
Why?
|
| Radiotherapy, Conformal | 1 | 2012 | 24 | 0.110 |
Why?
|
| Calibration | 1 | 2011 | 73 | 0.100 |
Why?
|
| Adenoma | 1 | 2012 | 132 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 624 | 0.090 |
Why?
|
| Spinal Cord | 1 | 2009 | 244 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 332 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1070 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2015 | 304 | 0.060 |
Why?
|
| NF-kappa B | 2 | 2016 | 432 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2015 | 397 | 0.060 |
Why?
|
| Cell Survival | 2 | 2016 | 901 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2018 | 2083 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2015 | 2688 | 0.050 |
Why?
|
| Animals | 5 | 2018 | 20877 | 0.050 |
Why?
|
| Humans | 7 | 2017 | 68525 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2323 | 0.040 |
Why?
|
| Time Factors | 2 | 2018 | 4655 | 0.040 |
Why?
|
| Mice | 3 | 2015 | 8472 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2018 | 50 | 0.040 |
Why?
|
| Bone Nails | 1 | 2018 | 32 | 0.040 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2018 | 33 | 0.040 |
Why?
|
| Bone Plates | 1 | 2018 | 49 | 0.040 |
Why?
|
| 4-1BB Ligand | 1 | 2016 | 5 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2016 | 52 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2016 | 84 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2016 | 233 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 128 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 196 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 46 | 0.030 |
Why?
|
| Male | 5 | 2018 | 37281 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 219 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 194 | 0.030 |
Why?
|
| Receptors, Interferon | 1 | 2014 | 8 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 7 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 132 | 0.030 |
Why?
|
| Piperidines | 1 | 2015 | 123 | 0.030 |
Why?
|
| Granzymes | 1 | 2014 | 19 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 195 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 294 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2014 | 77 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2014 | 62 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 499 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 852 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 1039 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2014 | 86 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 532 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 648 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 329 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 652 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 1199 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 508 | 0.030 |
Why?
|
| Cell Movement | 1 | 2014 | 630 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1173 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2015 | 446 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2015 | 705 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2550 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2014 | 1663 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1034 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 1692 | 0.020 |
Why?
|
| Blood Volume | 1 | 2009 | 47 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 2009 | 69 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2009 | 168 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2009 | 172 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 1293 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1640 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 2790 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 5300 | 0.020 |
Why?
|
| Aged | 2 | 2012 | 14842 | 0.020 |
Why?
|
| Middle Aged | 2 | 2012 | 21119 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2009 | 3702 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 4843 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2012 | 7028 | 0.010 |
Why?
|
| Female | 2 | 2012 | 38015 | 0.010 |
Why?
|
| Adult | 1 | 2009 | 21375 | 0.010 |
Why?
|